Receptor Protein-Tyrosine Kinases
"Receptor Protein-Tyrosine Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.
| Descriptor ID |
D020794
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400 D12.776.543.750.630
|
| Concept/Terms |
Receptor Protein-Tyrosine Kinases- Receptor Protein-Tyrosine Kinases
- Kinases, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinases, Receptor
- Receptor Protein Tyrosine Kinases
- Receptors, Protein-Tyrosine Kinase
- Protein-Tyrosine Kinase Receptors
- Receptors, Protein Tyrosine Kinase
- PTK Receptors
- Receptors, PTK
- Tyrosine Kinase Receptors
- Protein-Tyrosine Kinase Receptor
- Receptor, Protein-Tyrosine Kinase
- Receptor Protein-Tyrosine Kinase
- Kinase, Receptor Protein-Tyrosine
- Protein-Tyrosine Kinase, Receptor
- Receptor Protein Tyrosine Kinase
- Tyrosine Kinase Linked Receptors
|
Below are MeSH descriptors whose meaning is more general than "Receptor Protein-Tyrosine Kinases".
Below are MeSH descriptors whose meaning is more specific than "Receptor Protein-Tyrosine Kinases".
- Receptor Protein-Tyrosine Kinases
- c-Mer Tyrosine Kinase
- Discoidin Domain Receptors
- ErbB Receptors
- fms-Like Tyrosine Kinase 3
- Proto-Oncogene Proteins c-kit
- Proto-Oncogene Proteins c-met
- Proto-Oncogene Proteins c-ret
- Receptor Tyrosine Kinase-like Orphan Receptors
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Fibroblast Growth Factor, Type 2
- Receptor, Fibroblast Growth Factor, Type 3
- Receptor, Fibroblast Growth Factor, Type 4
- Receptor, IGF Type 1
- Receptor, Insulin
- Receptor, Macrophage Colony-Stimulating Factor
- Receptor, trkA
- Receptor, trkB
- Receptor, trkC
- Receptors, Eph Family
- Receptors, Platelet-Derived Growth Factor
- Receptors, TIE
- Receptors, Vascular Endothelial Growth Factor
This graph shows the total number of publications written about "Receptor Protein-Tyrosine Kinases" by people in this website by year, and whether "Receptor Protein-Tyrosine Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 5 | 1 | 6 |
| 1996 | 4 | 1 | 5 |
| 1997 | 1 | 0 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 2 | 3 | 5 |
| 2000 | 2 | 0 | 2 |
| 2001 | 3 | 3 | 6 |
| 2002 | 3 | 2 | 5 |
| 2003 | 6 | 1 | 7 |
| 2004 | 1 | 0 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 2 | 1 | 3 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
| 2017 | 4 | 2 | 6 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 1 | 3 |
| 2020 | 1 | 2 | 3 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 3 | 4 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor Protein-Tyrosine Kinases" by people in Profiles.
-
Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer. Invest New Drugs. 2024 Oct; 42(5):547-558.
-
Impact of Tumor-intrinsic Molecular Features on Survival and Acquired Tyrosine Kinase Inhibitor Resistance in ALK-positive NSCLC. Cancer Res Commun. 2024 03 14; 4(3):786-795.
-
Inhibition of CSF1R and KIT With Pexidartinib Reduces Inflammatory Signaling and Cell Viability in Endometriosis. Endocrinology. 2024 Feb 20; 165(4).
-
Advances in targets in inflammatory breast cancer. Int Rev Cell Mol Biol. 2024; 384:125-152.
-
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation. Diagn Pathol. 2024 Jan 10; 19(1):10.
-
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer. JAMA Netw Open. 2023 12 01; 6(12):e2347700.
-
Important Considerations for Real-World Analysis of Neurotrophic Tyrosine Receptor Kinase Fusion Cancer and Tropomyosin Receptor Kinase Inhibitors. JCO Precis Oncol. 2023 09; 7:e2300217.
-
Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer. Mol Cancer Ther. 2023 07 05; 22(7):818-832.
-
Single-cell transcriptomic analysis uncovers intratumoral heterogeneity and drug-tolerant persister in ALK-rearranged lung adenocarcinoma. Cancer Commun (Lond). 2023 08; 43(8):951-955.
-
DUSP22 rearrangement is associated with a distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica. 2023 06 01; 108(6):1604-1615.